Optimizing telemedicine to facilitate amyotrophic lateral sclerosis clinical trials

Raghav Govindarajan, James D. Berry, Sabrina Paganoni, Michael T. Pulley, Zachary Simmons

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Amyotrophic lateral sclerosis (ALS) has the largest drug pipeline among neuromuscular diseases, with over 160 companies actively involved in ALS research. There is a growing need to recruit trial participants, but ALS patients often have limited mobility and most ALS trials are conducted in a small number of major centers. These factors effectively limit patient participation, particularly for those in rural areas. The current coronavirus disease 2019 (COVID-19) pandemic has necessitated the more widespread use of telemedicine technology for clinical care, and has prompted consideration of its increased use for clinical trials. In this opinion piece, we describe the current state of telemedicine for recruitment, consenting, and screening of participants for clinical trials. We also summarize the available data on remote administration of outcome measures. Current challenges include validation of outcome measures for remote assessment, as well as technological, regulatory, and licensure barriers.

Original languageEnglish (US)
Pages (from-to)321-326
Number of pages6
JournalMuscle and Nerve
Issue number3
StatePublished - Sep 1 2020

All Science Journal Classification (ASJC) codes

  • Physiology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Physiology (medical)


Dive into the research topics of 'Optimizing telemedicine to facilitate amyotrophic lateral sclerosis clinical trials'. Together they form a unique fingerprint.

Cite this